Literature DB >> 6303264

High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses.

M R Cohen, R M Cohen, D Pickar, H Weingartner, D L Murphy.   

Abstract

Hypotheses of involvement of the endogenous opioid system (EOS) in the regulation of human behavior suggest that functional blockade of the EOS should have behavioral consequences. Clinical administration of the opiate receptor antagonist naloxone hydrochloride, however, has had little or inconsistent behavioral effects in normals. This may be attributable to the use of doses insufficient to yield a complete EOS blockade. To assess this explanation, normals were administered increasing doses of naloxone hydrochloride (0.3 to 4 mg/kg) in a single-blind design. Significant dose-dependent behavioral, hormonal, and physiological effects were found. With increasing doses of naloxone, volunteers demonstrated increasingly dysphoric affects, a deterioration of performance on memory testing, increasing systolic BP and respiratory rate, and increasing plasma cortisol and growth hormone levels. These results are consistent with the expected effects of increasing EOS blockade, and thus suggest that lower doses of naloxone used in previous clinical studies may not have been sufficient to produce a complete EOS blockade. Specifically, they suggest involvement of the EOS in the tonic regulation of normal human mood, memory, BP, respirations, and plasma growth hormone and cortisol levels.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6303264     DOI: 10.1001/archpsyc.1983.04390010023003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  Activity anorexia: An interplay between basic and applied behavior analysis.

Authors:  W D Pierce; W F Epling; P B Dews; W K Estes; W H Morse; W Van Orman; R J Herrnstein
Journal:  Behav Anal       Date:  1994

2.  Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability.

Authors:  M R Yeomans; P Wright; H A Macleod; J A Critchley
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Naloxone does not affect cigarette smoking.

Authors:  R Nemeth-Coslett; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

5.  A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke.

Authors:  F Federico; V Lucivero; P Lamberti; A Fiore; C Conte
Journal:  Ital J Neurol Sci       Date:  1991-12

6.  Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man.

Authors:  A F Martin del Campo; J H Dowson; J Herbert; E S Paykel
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

7.  Naltrexone, smoking behaviour and cigarette withdrawal.

Authors:  G Sutherland; J A Stapleton; M A Russell; C Feyerabend
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

8.  Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.

Authors:  Vanessa Minervini; Alex Disney; Stephen M Husbands; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2020-08-09       Impact factor: 4.530

9.  Naltrexone effects on cortisol secretion in women and men in relation to a family history of alcoholism: studies from the Oklahoma Family Health Patterns Project.

Authors:  William R Lovallo; Andrea C King; Noha H Farag; Kristen H Sorocco; Andrew J Cohoon; Andrea S Vincent
Journal:  Psychoneuroendocrinology       Date:  2012-05-08       Impact factor: 4.905

10.  Does naloxone reinstate secondary hyperalgesia in humans after resolution of a burn injury? A placebo-controlled, double-blind, randomized, cross-over study.

Authors:  Manuel P Pereira; Mads U Werner; Thomas K Ringsted; Michael C Rowbotham; Bradley K Taylor; Joergen B Dahl
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.